Filing Details

Accession Number:
0001181431-15-005710
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-04-09 17:20:32
Reporting Period:
2015-04-07
Filing Date:
2015-04-09
Accepted Time:
2015-04-09 17:20:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
885306 Cynosure Inc CYNO Electromedical & Electrotherapeutic Apparatus (3845) 043125110
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1191987 W Timothy Baker C/O Cynosure, Inc.
5 Carlisle Road
Westford MA 01886
President And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2015-04-07 44,935 $16.46 44,935 No 4 M Direct
Class A Common Stock Disposition 2015-04-07 44,935 $32.01 0 No 4 S Direct
Class A Common Stock Acquisiton 2015-04-08 65 $16.46 65 No 4 M Direct
Class A Common Stock Disposition 2015-04-08 65 $32.02 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Employee Stock Option (right to buy) Disposition 2015-04-07 44,935 $0.00 44,935 $16.46
Class A Common Stock Employee Stock Option (right to buy) Disposition 2015-04-08 65 $0.00 65 $16.46
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
65 2022-02-15 No 4 M Direct
0 2022-02-15 No 4 M Direct
Footnotes
  1. The sales price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $32.00 to $32.15 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  2. The option became exercisable as to approximately 8.33% of the shares on each three-month anniversary of the 2/15/2012 grant date.